Brittany C. Parker Kerrigan
University of Texas MD Anderson Cancer Center
CancerGene deliveryViral replicationPathologymicroRNAPermissiveMesenchymal stem cellImmunologyMicrovesiclesIn vivoTumor microenvironmentGlioblastomaOncolytic adenovirusImmunotherapyGliomaHamsterBrain tumorContext (language use)ImmunosuppressionStem cellTropismCancer researchMedicineCell cultureOncolytic virusBiologyImmune system
25Publications
9H-index
390Citations
Publications 27
Newest
#1Yuzaburo ShimizuH-Index: 3
#2Joy GuminH-Index: 28
Last. Juan FueyoH-Index: 58
view all 0 authors...
OBJECTIVE Delta-24-RGD is an oncolytic adenovirus that is capable of replicating in and killing human glioma cells. Although intratumoral delivery of Delta-24-RGD can be effective, systemic delivery would improve its clinical application. Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) obtained from healthy donors have been investigated as virus carriers. However, it is unclear whether BM-hMSCs can be derived from glioma patients previously treated with marrow-toxic chemotherapy or w...
Source
#1Lynette Phillips (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Shoudong Li (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Frederick F. Lang (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 13 authors...
BACKGROUND Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is b...
Source
#1Visish M. Srinivasan (University of Texas MD Anderson Cancer Center)H-Index: 13
#1Visish M. Srinivasan (University of Texas MD Anderson Cancer Center)H-Index: 13
Last. Frederick F. LangH-Index: 76
view all 4 authors...
Despite significant improvement in understanding of molecular underpinnings driving glioblastoma, there is minimal improvement in overall survival of patients. This poor outcome is caused in part by traditional designs of early phase clinical trials, which focus on clinical assessments of drug toxicity and response. Window of opportunity trials overcome this shortcoming by assessing drug-induced on-target molecular alterations in post-treatment human tumor specimens. This article provides an ove...
Source
#1Visish M. Srinivasan (BCM: Baylor College of Medicine)H-Index: 13
#2Joy Gumin (BCM: Baylor College of Medicine)
Last. Peter Kan (BCM: Baylor College of Medicine)H-Index: 2
view all 13 authors...
Background Delta-24-RGD, an oncolytic adenovirus, shows promise against glioblastoma. To enhance virus delivery, we recently demonstrated that human bone marrow-derived mesenchymal stem cells loaded with Delta-24-RGD (hMSC-D24) can eradicate glioblastomas in mouse models. There are no studies examining the safety of endovascular selective intra-arterial (ESIA) infusions of MSC-D24 in large animals simulating human clinical situations. Objective To perform canine preclinical studies testing the f...
3 CitationsSource
#2Anwar HossainH-Index: 20
Last. Sricharan GopakumarH-Index: 2
view all 0 authors...
Source
#1Malcolm F. McDonald (BCM: Baylor College of Medicine)
#2Anwar Hossain (University of Texas MD Anderson Cancer Center)H-Index: 20
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 13 authors...
Source
#1Lynette Phillips (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Joy Gumin (University of Texas MD Anderson Cancer Center)H-Index: 28
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 10 authors...
Source
#1Sanjay K. Singh (University of Texas MD Anderson Cancer Center)H-Index: 21
#2Maxime Munyeshyaka (University of Texas MD Anderson Cancer Center)
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 8 authors...
Source
#1Nisha Giridharan (University of Texas MD Anderson Cancer Center)H-Index: 1
#2Isabella C. Glitza Oliva (University of Texas MD Anderson Cancer Center)H-Index: 8
Last. Sherise D. Ferguson (University of Texas MD Anderson Cancer Center)H-Index: 22
view all 6 authors...
Dynamic interplay between cancer cells and the surrounding microenvironment is a feature of the metastatic process. Successful metastatic brain colonization requires complex mechanisms that ultimately allow tumor cells to adapt to the unique microenvironment of the central nervous system, evade immune destruction, survive, and grow. Accumulating evidence suggests that components of the brain tumor microenvironment (TME) play a vital role in the metastatic cascade. In this review, the authors sum...
1 CitationsSource
#1Visish M. Srinivasan (University of Texas MD Anderson Cancer Center)H-Index: 13
#1Visish M. Srinivasan (University of Texas MD Anderson Cancer Center)H-Index: 13
Last. Peter KanH-Index: 40
view all 10 authors...
OBJECTIVE: Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) have been used in clinical trials for the treatment of several neurological disorders. MSCs have been explored as a delivery modality for targeted viral therapeutic agents in the treatment of intracranial pathologies. Delta-24-RGD, a tumor-selective oncolytic adenovirus designed to target malignant glioma cells, has been shown to be effective in animal models and in a recent clinical trial. However, the most efficient strateg...
4 CitationsSource